Dual‑targeted radioligand therapy with [177Lu]Lu‑DOTATATE plus [177Lu]Lu‑DOTA‑IBA for bone metastases from neuroendocrine neoplasms: a prospective pilot study
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8203-8216
DOI: 10.1007/s00259-026-08125-5 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.08.2026. Verfasst von Shumao Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, PR China. Hauptthemen laut MEDLINE: Organometallic Compounds, Neuroendocrine Tumors, Octreotide, Bone Neoplasms. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Gansu Province.
Abstract (Originalsprache)
PURPOSE: To evaluate the feasibility, safety and preliminary efficacy of dual-targeted radioligand therapy combining [177Lu]Lu-DOTATATE and [177Lu]Lu-DOTA-IBA in patients with bone metastases from neuroendocrine neoplasms (NENs). METHODS: This prospective, single-center, single-arm study enrolled 30 patients with bone metastases from NENs to receive combined [177Lu]Lu-DOTATATE and [177Lu]Lu-DOTA-IBA therapy. Treatment response was assessed using RECIST 1.1 and SSTR-PERCIST for all lesions, and modified M.D. Anderson criteria (MDAC) for bone metastases. Pain palliation assessed by the Visual Analogue Scale (VAS). Treatment-related adverse events (TRAEs) were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Progression-free survival (PFS) was performed using the Kaplan-Meier method. RESULTS: A total of 95 treatment cycles were administered. The overall bone pain relief rate was 95.9%, with complete pain resolution in 41.7% of patients. Among 24 evaluable patients, the objective response rates (ORR) were 16.7% by RECIST 1.1, 50% by SSTR-PERCIST, and 29.2% by MDAC. The corresponding disease control rates (DCR) were 79.2%, 79.2%, and 87.5%, respectively. Subgroup analyses revealed comparable ORRs and DCRs between GEP-NENs (n = 14) and non-GEP-NENs (n = 10) across all three criteria. Semi-Quantitative PET/CT parameters, including STV, SUVmax, SUVmean, TLS, TBR, SULpeak, SLD and TBV decreased significantly after treatment (all P < 0.05). Absorbed doses to critical organs remained within safe thresholds. No grade ≥ 4 AEs occurred. No significant difference in PFS was observed between the two subgroups (log-rank P = 0.828). CONCLUSION: Our findings suggest that dual-targeted radioligand therapy with [177Lu]Lu-DOTATATE plus [177Lu]Lu-DOTA-IBA is feasible and well-tolerated, and may provide preliminary antitumor efficacy and pain palliation. However, due to the single-arm design and limited sample size, its definitive anti-tumor efficacy requires confirmation in larger controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, PR China.
- Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Luzhou, 646000, Sichuan, PR China.
- Institute of Nuclear Medicine, Southwest Medical University, No 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, PR China.
- Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, PR China.
- Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, PR China. 1415420329@qq.com.
- Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Luzhou, 646000, Sichuan, PR China. 1415420329@qq.com.
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Gansu Province
Zitieren
APA
Zhang, S., Deng, J., Zhang, N., Bai, X., Li, B., Qi, C., Yang, J., Zhang, Y., & Chen, Y. (2026). Dual‑targeted radioligand therapy with [177Lu]Lu‑DOTATATE plus [177Lu]Lu‑DOTA‑IBA for bone metastases from neuroendocrine neoplasms: a prospective pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8203-8216. https://doi.org/10.1007/s00259-026-08125-5
Vancouver
Zhang S, Deng J, Zhang N, Bai X, Li B, Qi C, et al. Dual‑targeted radioligand therapy with [177Lu]Lu‑DOTATATE plus [177Lu]Lu‑DOTA‑IBA for bone metastases from neuroendocrine neoplasms: a prospective pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8203-8216. doi:10.1007/s00259-026-08125-5
BibTeX
@article{Zhang2026,
author = {Zhang, Shumao and Deng, Jia and Zhang, Na and Bai, Xuecheng and Li, Bo and Qi, Chi and Yang, Jian and Zhang, Yu and Chen, Yue},
title = {Dual‑targeted radioligand therapy with [177Lu]Lu‑DOTATATE plus [177Lu]Lu‑DOTA‑IBA for bone metastases from neuroendocrine neoplasms: a prospective pilot study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8203--8216},
doi = {10.1007/s00259-026-08125-5}
}
EUVIMED